Safety of antithrombotic drugs in patients with atrial fibrillation and non-end-stage chronic kidney disease: Meta-analysis and systematic review

Thrombosis Research

Volumn 137, Issue , 2016, Pages 46-52

  Bai, Ying ^a   Chen, Hui ^b   Yang, Yi ^a   Li, Li ^a   Liu, Xin Yao ^a   Shi, Xu Bo ^a   Ma, Chang Sheng ^a,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Direct oral anticoagulants; Major bleeding; Non end stage chronic kidney disease; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; PLACEBO; WARFARIN; FIBRINOLYTIC AGENT;

ARTICLE; ATRIAL FIBRILLATION; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; COCHRANE LIBRARY; DRUG SAFETY; DRUG USE; END STAGE RENAL DISEASE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MEDLINE; META ANALYSIS; NON END STAGE CHRONIC KIDNEY DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; AGED; CHEMICALLY INDUCED; COMORBIDITY; FEMALE; HEMORRHAGE; INCIDENCE; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; THROMBOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COMORBIDITY; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; THROMBOSIS; WARFARIN;

EID: 84952639951     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.11.020     Document Type: Article

References (28)

1. I.E. Albertsen, L.H. Rasmussen, T.F. Overvad, T. Graungaard, T.B. Larsen, and G.Y. Lip Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis Stroke 44 2013 1329 1336
2. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, and et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Eur. Heart J. 31 2010 2369 2429
3. C.T. January, L.S. Wann, J.S. Alpert, H. Calkins, J.E. Cigarroa, J.C. Cleveland Jr., and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J. Am. Coll. Cardiol. 64 2014 e1 76
4. S.H. Hohnloser Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma J. Am. Coll. Cardiol. 57 2011 181 183
5. W.T. Zeng, X.T. Sun, K. Tang, W.Y. Mei, L.J. Liu, Q. Xu, and et al. Risk of thromboembolic events in atrial fibrillation with chronic kidney disease Stroke. 46 2015 157 163
6. A. King Atrial fibrillation: HAS-BLED - a new risk score to predict bleeding in patients with AF Nat. Rev. Cardiol. 8 2011 64
7. H. Reinecke, E. Brand, R. Mesters, W.R. Schäbitz, M. Fisher, H. Pavenstädt, and et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease J. Am. Soc. Nephrol. 20 2009 705 711
8. P.S. Sharma, P. Boruah, I. Ahmed, and S. Pancholy Bleeding as important as ischemic stroke in predicting mortality in atrial fibrillation J. Am. Coll. Cardiol. 59 2012 (Abstract no. E672)
9. J.J. Carrero, M. Evans, K. Szummer, J. Spaak, L. Lindhagen, R. Edfors, and et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation J. Am. Med. Assoc. 311 2014 919 928
10. J.B. Olesen, G.Y. Lip, A.L. Kamper, K. Hommel, L. Køber, D.A. Lane, and et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease N. Engl. J. Med. 367 2012 625 635
11. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 2009 1139 1151
12. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, and et al. Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 2011 981 992
13. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 2011 883 891
14. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm.
15. A.P. Verhagen, H.C. de Vet, R.A. de Bie, A.G. Kessels, M. Boers, L.M. Bouter, and et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus J. Clin. Epidemiol. 51 1998 1235 1241
16. G. Ntaios, V. Papavasileiou, H.C. Diener, K. Makaritsis, and P. Michel Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials Stroke 43 2012 3298 3304
17. H.M. Lai, W.S. Aronow, P. Kalen, S. Adapa, K. Patel, A. Goel, and et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin Int. J. Nephrol. Renov. Dis. 2 2009 33 37
18. N.A. Limdi, T.M. Beasley, M.F. Baird, J.A. Goldstein, G. McGwin, D.K. Arnett, and et al. Kidney function influences warfarin responsiveness and hemorrhagic complications J. Am. Soc. Nephrol. 20 2009 912 921
19. C.C. Chang, H.H. Liou, C.L. Wu, C.B. Chang, Y.J. Chang, P.F. Chiu, and et al. Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation Clin. Interv. Aging. 8 2013 523 529
20. R.G. Hart, L.A. Pearce, R.W. Asinger, and C.A. Herzog Warfarin in atrial fibrillation patients with moderate chronic kidney disease Clin. J. Am. Soc. Nephrol. 6 2011 2599 2604
21. F. Khalid, W. Qureshi, S. Qureshi, Z. Alirhayim, K. Garikapati, and I. Patsias Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage Ren. Fail. 35 2013 1228 1235
22. S.H. Hohnloser, Z. Hijazi, L. Thomas, J.H. Alexander, J. Amerena, M. Hanna, and et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur. Heart J. 33 2012 2821 2830
23. Z. Hijazi, S.H. Hohnloser, J. Oldgren, U. Andersson, S.J. Connolly, J.W. Eikelboom, and et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Circulation 129 2014 961 970
24. J.P. Piccini, S.R. Stevens, Y. Chang, D.E. Singer, Y. Lokhnygina, A.S. Go, and et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts Circulation 127 2013 224 232
25. K.A. Fox, J.P. Piccini, D. Wojdyla, R.C. Becker, J.L. Halperin, C.C. Nessel, and et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Eur. Heart J. 32 2011 2387 2394
26. E.M. Hylek, A.S. Go, Y. Chang, N.G. Jensvold, L.E. Henault, J.V. Selby, and et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N. Engl. J. Med. 349 2003 1019 1026
27. K.M. Jönsson, M. Wieloch, G. Sterner, U. Nyman, S. Elmståhl, G. Engström, and et al. Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden Thromb. Res. 128 2011 341 345
28. N.S. Roskell, M. Samuel, H. Noack, and B.U. Monz Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies Europace 15 2013 787 797